Letter-to-the-editor: Ethical concerns over stem cell research
By Osagie Obasogie,
Los Angeles Times
| 08. 29. 2006
The recent breakthrough that may allow scientists to create human embryonic stem cells without destroying embryos may move stem cell conversations beyond the deliberative quagmire of abortion politics and embryos' moral status. But it would be misguided to think that whether or not an embryo is destroyed marks the only ethical or social concern. Stem cell research may lead to therapies for devastating diseases. But will designer medicines premised on stem cell research be affordable to anyone other than the wealthy, particularly after California's taxpayers invested nearly $6 billion in their development? How will researchers obtain the eggs necessary to pursue this research, and how will this affect women's health? How can we oversee these technologies and their applications while ensuring that a growing industry with the keys to life's building blocks acts in the public's interest?
How embryos are treated with regard to stem cell research is unquestionably important. But equally important is how we treat each other.
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...